|
1
|
Park JH and Brentjens RJ: Adoptive
immunotherapy for B-cell malignancies with autologous chimeric
antigen receptor modified tumor targeted T cells. Discov Med.
9:277–288. 2010.PubMed/NCBI
|
|
2
|
Castro FV, Al-Muftah M, Mulryan K, Jiang
HR, Drijfhout JW, Ali S, Rutkowski AJ, Kalaitsidou M, Gilham DE and
Stern PL: Regulation of autologous immunity to the mouse 5T4
oncofoetal antigen: Implications for immunotherapy. Cancer Immunol
Immunother. 61:1005–1018. 2012. View Article : Google Scholar
|
|
3
|
Steeland S, Libert C and Vandenbroucke RE:
A new venue of TNF targeting. Int J Mol Sci. 19:E14422018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kopylov U, Ben-Horin S, Zmora O, Eliakim R
and Katz LH: Anti-tumor necrosis factor and postoperative
complications in Crohn's disease: Systematic review and
meta-analysis. Inflamm Bowel Dis. 18:2404–2413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawalec P, Mikrut A, Wisniewska N and Pilc
A: Tumor necrosis factor-alpha antibodies (infliximab, adalimumab
and certolizumab) in Crohn's disease: Systematic review and
meta-analysis. Arch Med Sci. 9:765–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marchioni RM and Lichtenstein GR: Tumor
necrosis factor-alpha inhibitor therapy and fetal risk: A
systematic literature review. World J Gastroenterol. 19:2591–2602.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Laharie D, Bourreille A, Branche J, Allez
M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J,
et al: Ciclosporin versus infliximab in patients with severe
ulcerative colitis refractory to intravenous steroids: A parallel,
open-label randomised controlled trial. Lancet. 380:1909–1915.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh S, Heien HC, Sangaralingham LR,
Schilz SR, Kappelman MD, Shah ND and Loftus EV: Comparative
effectiveness and safety of infliximab and adalimumab in patients
with ulcerative colitis. Aliment Pharmacol Ther. 43:994–1003. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marehbian J, Arrighi HM, Hass S, Tian H
and Sandborn WJ: Adverse events associated with common therapy
regimens for moderate-to-severe Crohn's disease. Am J
Gastroenterol. 104:2524–2533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
No authors listed. Can super-antibody
drugs be tamed? Nature. 440:855–856. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rolinski J and Hus I: Breaking
immunotolerance of tumors: A new perspective for dendritic cell
therapy. J Immunotoxicol. 11:311–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park KB, Lim BK, Ye MB, Chung SY and Nam
JH: A peptide vaccine based on a B-cell epitope on the VP1 protein
of entero-virus 70 induces a strong antibody response. Acta Virol.
56:337–342. 2012. View Article : Google Scholar
|
|
13
|
Paul S and Piontkivska H: Frequent
associations between CTL and T-Helper epitopes in HIV-1 genomes and
implications for multi-epitope vaccine designs. BMC Microbiol.
10:2122010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haro I and Gómara MJ: Design of synthetic
peptidic constructs for the vaccine development against viral
infections. Curr Protein Pept Sci. 5:425–433. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Yang J, Fan D, Tao H, Wang H and
Yu T: Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted
CTL epitope and elicits potent immunological antitumor effects in
vitro with an 8-branched design. Oncol Rep. 29:1955–1961. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Yang J, Cai Y, Jin N, Wang H and
Yu T: Multiple antigenic polypeptide composed of heparanase Bcell
epitopes shrinks human hepatocellular carcinoma in mice. Oncol Rep.
33:1248–1256. 2015. View Article : Google Scholar
|
|
17
|
Jia JY, Zhou HZ and Tang J: The study of
mouse TNF-α functional domain and its neutralizing antibody binding
site. Prog Biochem Biophys. 36:424–430. 2009.In Chinese.
|
|
18
|
Boraschi D and Tagliabue A: Interleukin-1
and interleukin-1 fragments as vaccine adjuvants. Methods.
19:108–113. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chakraborty S, Chakravorty R, Ahmed M,
Rahman A, Waise TM, Hassan F, Rahman M and Shamsuzzaman S: A
computational approach for identification of epitopes in dengue
virus envelope protein: A step towards designing a universal dengue
vaccine targeting endemic regions. In Silico Biol. 10:235–246.
2010.PubMed/NCBI
|
|
20
|
Yang XS, Wang HQ, Yuan QF, Xie Y, Yao ZB,
Ye XZ, Wu JM and Zhou AG: Directly synthesize Aβ_(1-15) peptide
vaccine by fmoc solid-phase peptide synthesis and study its immune
activity. J Sun Yat Sen Uni. 27:121–125. 2006.In Chinese.
|
|
21
|
Wang J, Sun N, Zhou C, Zhou X, Lu J, Wang
C and Che H: Food proteins from different allergen families
sensitize balb/c mice to family-specific immune responses. J
Immunotoxicol. 11:172–179. 2014. View Article : Google Scholar
|
|
22
|
Zhang J, Cui Y, Wu Y, Wang H and Ke J:
Prediction and identification of Bcell epitopes for tumor necrosis
factoralpha. Mol Med Rep. 16:3439–3444. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Murano M, Maemura K, Hirata I, Toshina K,
Nishikawa T, Hamamoto N, Sasaki S, Saitoh O and Katsu K:
Therapeutic effect of intracolonically administered nuclear factor
kappa B (p65) antisense oligonucleotide on mouse dextran sulphate
sodium (DSS)-induced colitis. Clin Exp Immunol. 120:51–58. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kihara N, de la Fuente SG, Fujino K,
Takahashi T, Pappas TN and Mantyh CR: Vanilloid receptor-1
containing primary sensory neurones mediate dextran sulphate sodium
induced colitis in rats. Gut. 52:713–719. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sureshbabu A, Syed MA, Boddupalli CS,
Dhodapkar MV, Homer RJ, Minoo P and Bhandari V: Conditional
overexpres-sion of TGFβ1 promotes pulmonary inflammation, apoptosis
and mortality via TGFβR2 in the developing mouse lung. Respir Res.
16:42015. View Article : Google Scholar
|
|
26
|
Thorlund K, Druyts E, Mills EJ, Fedorak RN
and Marshall JK: Adalimumab versus infliximab for the treatment of
moderate to severe ulcerative colitis in adult patients naive to
anti-TNF therapy: An indirect treatment comparison meta-analysis. J
Crohns Colitis. 8:571–581. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fausel R and Afzali A: Biologics in the
management of ulcerative colitis-comparative safety and efficacy of
TNF-alpha antagonists. Ther Clin Risk Manag. 11:63–73. 2015.
|
|
28
|
Ben-Horin S, Kopylov U and Chowers Y:
Optimizing anti-TNF treatments in inflammatory bowel disease.
Autoimmun Rev. 13:24–30. 2014. View Article : Google Scholar
|
|
29
|
de Mattos BR, Garcia MP, Nogueira JB,
Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM
and Simioni PU: Inflammatory bowel disease: An overview of immune
mechanisms and biological treatments. Mediators Inflamm.
2015:4930122015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chey WY: Infliximab for patients with
refractory ulcerative colitis. Inflamm Bowel Dis. 7(Suppl 1):
S30–S33. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okamoto R and Watanabe M: Functional
relevance of intestinal epithelial cells in inflammatory bowel
disease. Nihon Rinsho Meneki Gakkai Kaishi. 39:522–527. 2016.
View Article : Google Scholar
|
|
32
|
Landy J, Ronde E, English N, Clark SK,
Hart AL, Knight SC, Ciclitira PJ and Al-Hassi HO: Tight junctions
in inflammatory bowel diseases and inflammatory bowel disease
associated colorectal cancer. World J Gastroenterol. 22:3117–3126.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Noth R, Stüber E, Häsler R, Nikolaus S,
Kühbacher T, Hampe J, Bewig B, Schreiber S and Arlt A: Anti-TNF-α
antibodies improve intestinal barrier function in Crohn's disease.
J Crohns Colitis. 6:464–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Di Sabatino A, Pender SL, Jackson CL,
Prothero JD, Gordon JN, Picariello L, Rovedatti L, Docena G,
Monteleone G, Rampton DS, et al: Functional modulation of Crohn's
disease myofibroblasts by anti-tumor necrosis factor antibodies.
Gastroenterology. 133:137–149. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li JY, Lu Y and Fu XB: The significance of
changes in diamine oxidase activity in intestinal injury after
trauma. Chin Crit Care Med. 12:482–484. 2000.In Chinese.
|
|
36
|
Leaphart CL and Tepas JJ III: The gut is a
motor of organ system dysfunction. Surgery. 141:563–569. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ivanov AI, Nusrat A and Parkos CA:
Endocytosis of the apical junctional complex: Mechanisms and
possible roles in regulation of epithelial barriers. Bioessays.
27:356–365. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Furuse M, Hirase T, Itoh M, Nagafuchi A,
Yonemura S and Tsukita S: Occludin: A novel integral membrane
protein local-izing at tight junctions. J Cell Biol. 123:1777–1788.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wardill HR, Bowen JM, Al-Dasooqi N,
Sultani M, Bateman E, Stansborough R, Shirren J and Gibson RJ:
Irinotecan disrupts tight junction proteins within the gut:
Implications for chemotherapy-induced gut toxicity. Cancer Biol
Ther. 15:236–244. 2014. View Article : Google Scholar
|
|
40
|
Shang HX, Wang AQ, Bao CH, Wu HG, Chen WF,
Wu LY, Ji R, Zhao JM and Shi Y: Moxibustion combined with
acupuncture increases tight junction protein expression in Crohn's
disease patients. World J Gastroenterol. 21:4986–4996. 2015.
View Article : Google Scholar : PubMed/NCBI
|
